Allowash XG

Allowash XG® is a patented and proprietary sterilization process that removes greater than 99% of bone marrow and blood elements from the internal bone matrix. Allowash XG renders allograft bio-implants sterile without compromising their biomechanical or biochemical properties.

Donor tissue goes through a stringent screening routine and is recovered in strict aseptic conditions. Allograft bio-implants then go through serological testing to further control and eliminate incoming bioburden. The allograft bio-implants are processed and preserved in facilities that maintain cleanliness levels that minimize or eliminate environmentally induced graft contamination. Allograft bio-implants are cleaned with key solutions that are forced into and through the bone matrix and then directed to waste, resulting in the lysis of cells and cleaning of the tissues. The decontamination, disinfection and cleaning regimens for the allograft bio-implants remove and eliminate viruses and bacteria. The final step is sterilization with a controlled and validated dose of gamma irradiation administered at low temperatures after the allograft bio-implants is packaged.

Allowash XG renders allograft bio-implants sterile without compromising the biomechanical or biochemical properties of allograft tissue for their intended surgical applications. This is achieved by:

• Removing greater than 99% of extractable elements from the bone matrix
• Ensuring a Sterility Assurance Level (SAL) of 10-6 through chemical treatment and sterilization steps
• Inactivating enveloped and non-enveloped viruses

Allowash XG renders allograft bio-implants sterile without compromising the biomechanical or biochemical properties of allograft tissue for their intended surgical applications. This is achieved by: Removing greater than 99% of extractable elements from the bone matrix Ensuring a Sterility Assurance Level (SAL) of 10-6 through chemical treatment and sterilization steps Inactivating enveloped and non-enveloped viruses

Allowash XG gives you sterility without compromising the biomechanical and biochemical properties of allograft tissue needed for surgical applications. Since the introduction of Allowash® in 1994, and the introduction of Allowash XG® in 2004, LifeNet Health has delivered over 2 million allograft bio-implants with no incident of disease transmission.